Literature DB >> 7189

In vitro activity of josamycin against aerobic gram-positive cocci and anaerobes.

E L Westerman, T W Williams, N Moreland.   

Abstract

Josamycin, a new macrolide antibiotic, was compared with ampicillin, erythromycin, and clindamycin in vitro against 25 isolates each of pneumococci, enterococci, Staphylococcus aureus, S. epidermidis, and nonenterococcal hemolytic streptococci and against 25 anaerobes including 10 Bacteroides fragilis. Minimal inhibitory concentration and minimal bactericidal concentration data were obtained for the aerobic organisms, using serial twofold tube dilutions in Mueller-Hinton broth. Minimal inhibitory concentrations were determined for the anaerobes by the agar dilution technique. Josamycin was comparable to erythromycin and clindamycin in activity against the pneumococci, streptococci, and staphylococci and was more active than clindamycin against enterococci. It was somewhat less active than ampicillin against enterococci and S. epidermidis and showed its greatest in vitro activity against anaerobes, being comparable to clindamycin.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 7189      PMCID: PMC429662          DOI: 10.1128/AAC.9.6.988

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  3 in total

1.  The antibacterial action of erythromycin.

Authors:  T H HAIGHT; M FINLAND
Journal:  Proc Soc Exp Biol Med       Date:  1952-10

2.  Influence of food and hepatobiliary disease on the excretion of josamycin.

Authors:  T Bergan; P Tolås; B Oydvin
Journal:  Pharmacology       Date:  1972       Impact factor: 2.547

3.  Standardized antimicrobial disc susceptibility testing of anaerobic bacteria. I. Susceptibility of Bacteroides fragilis to tetracycline.

Authors:  V L Sutter; Y Y Kwok; S M Finegold
Journal:  Appl Microbiol       Date:  1972-02
  3 in total
  7 in total

1.  In vitro activity of rosamicin, josamycin, erythromycin, and clindamycin against beta-lactamase-nagative and beta-lactamase-positive strains of Neisseria gonorrhoeae.

Authors:  J W Biddle; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

2.  Disk diffusion susceptibility testing of two macrolide antimicrobial agents: revised interpretive criteria for erythromycin and preliminary guidelines for roxithromycin (RU 965).

Authors:  R N Jones; A L Barry; P C Fuchs; C Thornsberry
Journal:  J Clin Microbiol       Date:  1986-08       Impact factor: 5.948

3.  Josamycin-induced pedal oedema.

Authors:  X Bosch; E Pedrol; X Casado; A Urbano-Marquez
Journal:  BMJ       Date:  1993-07-03

4.  In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria.

Authors:  T Barlam; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

5.  Synergy between RU 28965 (roxithromycin) and human neutrophils for bactericidal activity in vitro.

Authors:  M T Labro; N Amit; C Babin-Chevaye; J Hakim
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

6.  In vivo effects of josamycin, erythromycin, and placebo therapy on nasal carriage of Staphylococcus aureus.

Authors:  S Z Wilson; R R Martin; M Putman
Journal:  Antimicrob Agents Chemother       Date:  1977-03       Impact factor: 5.191

7.  In vitro evaluation of three new macrolide antimicrobial agents, RU28965, RU29065, and RU29702, and comparisons with other orally administered drugs.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.